<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01309854</url>
  </required_header>
  <id_info>
    <org_study_id>D4300C00014</org_study_id>
    <nct_id>NCT01309854</nct_id>
  </id_info>
  <brief_title>Effects of Administration of Fostamatinib on Blood Concentrations of Pioglitazone in Healthy Subjects</brief_title>
  <official_title>An Open-Label, Single Center Study to Assess the Pharmacokinetics of Pioglitazone in Healthy Subjects When Administered Alone and in Combination With Fostamatinib 100 mg Twice Daily</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the drug interaction between fostamatinib and
      pioglitazone by comparing the safety, tolerability and plasma concentration of pioglitazone
      when administered alone and with fostamatinib in healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess pharmacokinetics (PK) of pioglitazone including but not limited to AUC and Cmax</measure>
    <time_frame>Period 1: Pre-dose to 48h post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess pharmacokinetics (PK) of pioglitazone including but not limited to AUC and Cmax</measure>
    <time_frame>Period 2: Pre-dose to 48h post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess pharmacokinetics (PK) of hydroxypioglitazone (active metabolite) including but not limited to AUC and Cmax</measure>
    <time_frame>Period 1: Pre-dose to 48h post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess pharmacokinetics (PK) of hydroxypioglitazone (active metabolite) including but not limited to AUC and Cmax</measure>
    <time_frame>Period 2: Pre-dose to 48h post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To examine the safety and tolerability</measure>
    <time_frame>From screening, Day -1 to Day 9 and follow up visit (Day 16)</time_frame>
    <description>To examine the safety and tolerability of fostamatinib in combination with pioglitazone. Assessments include: Adverse events, laboratory assessments, vital signs, physical examination and 12-lead electrocardiogram</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Healthy Volunteers</condition>
  <condition>Pharmacokinetics</condition>
  <condition>Pioglitazone</condition>
  <condition>Drug-drug Interaction</condition>
  <condition>Amount of Pioglitazone in Blood</condition>
  <arm_group>
    <arm_group_label>pioglitazone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>pioglitazone and fostamatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fostamatinib</intervention_name>
    <description>oral tablets, 100mg (2 X 50mg) twice daily for 8 days</description>
    <arm_group_label>pioglitazone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pioglitazone</intervention_name>
    <description>oral tablets, 30mg single dose per period</description>
    <arm_group_label>pioglitazone</arm_group_label>
    <arm_group_label>pioglitazone and fostamatinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of informed consent prior to any study specific procedures

          -  Males or females (of non-child bearing potential) aged 18 to 55 years (inclusive)

          -  Minimum weight of 50 kg and a body mass index (BMI) of 18 to 35 kg/m2 (inclusive)

          -  Males must be willing to use barrier contraception ie, condoms, from the first
             administration until 2 weeks after the last administration of the investigational
             product

        Exclusion Criteria:

          -  History or presence of gastrointestinal, hepatic or renal disease (except for
             cholecystectomy)

          -  Any clinically significant illness, medical/surgical procedure or trauma within 4
             weeks of the first administration of the investigational product

          -  Subjects who smoke more than 5 cigarettes or the equivalent in tobacco per day

          -  Absolute neutrophil count of less than 2500/mm3 or 2.5 x 109/L

          -  Any previous treatment with fostamatinib or pioglitazone
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Layton, MD, MRCP</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carlos Prendes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintiles Overland Park, Phase 1 Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 21, 2011</study_first_submitted>
  <study_first_submitted_qc>March 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2011</study_first_posted>
  <last_update_submitted>July 6, 2011</last_update_submitted>
  <last_update_submitted_qc>July 6, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 7, 2011</last_update_posted>
  <responsible_party>
    <name_title>Mark Layton / Medical Science Director</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>healthy volunteers</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>Rheumatoid arthritis</keyword>
  <keyword>RA</keyword>
  <keyword>fostamatinib</keyword>
  <keyword>pioglitazone</keyword>
  <keyword>drug-drug interaction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

